Aptose Biosciences (APTO)
(Delayed Data from NSDQ)
$0.40 USD
+0.04 (9.70%)
Updated Sep 17, 2024 03:56 PM ET
After-Market: $0.40 0.00 (-1.19%) 6:48 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Cash flow Statements
Fiscal Year End for Aptose Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -51.21 | -41.82 | -65.35 | -55.24 | -26.28 |
Depreciation/Amortization & Depletion | 0.47 | 0.53 | 0.62 | 0.61 | 0.61 |
Net Change from Assets/Liabilities | 2.41 | 3.77 | 1.52 | -0.26 | 1.89 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 3.75 | 5.20 | 19.91 | 21.00 | 2.22 |
Net Cash From Operating Activities | -44.59 | -32.32 | -43.30 | -33.89 | -21.56 |
Property & Equipment | -0.03 | -0.02 | -0.21 | -0.08 | -0.10 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 9.99 | 30.09 | -35.00 | 12.71 | -17.27 |
Other Investing Activities | 0.00 | 0.00 | -35.00 | 12.71 | 0.00 |
Net Cash from Investing Activities | 9.96 | 30.07 | -35.21 | 12.63 | -17.37 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 6.91 | 0.12 | 0.23 | 58.98 | 103.89 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | -0.17 | -0.44 |
Net Cash from Financing Activities | 6.91 | 0.12 | 0.23 | 58.81 | 103.45 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 |
Net Change In Cash & Equivalents | -27.72 | -2.14 | -78.28 | 37.55 | 64.54 |
Cash at Beginning of Period | 36.97 | 39.11 | 117.39 | 79.84 | 15.30 |
Cash at End of Period | 9.25 | 36.97 | 39.11 | 117.39 | 79.84 |
Diluted Net EPS | -7.58 | -6.75 | -10.94 | -10.04 | -7.80 |
Fiscal Year End for Aptose Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -16.89 | -9.64 | -51.21 | -39.25 | -27.81 |
Depreciation/Amortization & Depletion | 0.21 | 0.11 | 0.47 | 0.36 | 0.25 |
Net Change from Assets/Liabilities | -1.99 | -3.08 | 2.41 | 0.31 | 0.04 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 1.13 | 0.85 | 3.75 | 3.26 | 2.73 |
Net Cash From Operating Activities | -17.54 | -11.76 | -44.59 | -35.33 | -24.80 |
Property & Equipment | 0.02 | 0.00 | -0.03 | -0.03 | -0.03 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | -1.99 | 9.99 | 8.05 | -4.90 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | -4.90 |
Net Cash from Investing Activities | 0.02 | -1.99 | 9.96 | 8.02 | -4.93 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 16.78 | 11.85 | 6.91 | 6.07 | 1.16 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.18 | 0.00 | 0.00 | -0.01 | -0.01 |
Net Cash from Financing Activities | 16.60 | 11.85 | 6.91 | 6.06 | 1.15 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -0.92 | -1.91 | -27.72 | -21.25 | -28.57 |
Cash at Beginning of Period | 9.25 | 9.25 | 36.97 | 36.97 | 36.97 |
Cash at End of Period | 8.33 | 7.35 | 9.25 | 15.72 | 8.40 |
Diluted Net EPS | -0.43 | -0.73 | -1.30 | -1.76 | -2.27 |